Xencor (XNCR) Competitors $8.60 +0.10 (+1.18%) Closing price 04:00 PM EasternExtended Trading$8.56 -0.04 (-0.52%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XNCR vs. TARS, IDYA, OCUL, MLYS, IBRX, DNLI, IRON, BEAM, CNTA, and BLTEShould you be buying Xencor stock or one of its competitors? The main competitors of Xencor include Tarsus Pharmaceuticals (TARS), IDEAYA Biosciences (IDYA), Ocular Therapeutix (OCUL), Mineralys Therapeutics (MLYS), ImmunityBio (IBRX), Denali Therapeutics (DNLI), Disc Medicine (IRON), Beam Therapeutics (BEAM), Centessa Pharmaceuticals (CNTA), and Belite Bio (BLTE). These companies are all part of the "pharmaceutical products" industry. Xencor vs. Its Competitors Tarsus Pharmaceuticals IDEAYA Biosciences Ocular Therapeutix Mineralys Therapeutics ImmunityBio Denali Therapeutics Disc Medicine Beam Therapeutics Centessa Pharmaceuticals Belite Bio Tarsus Pharmaceuticals (NASDAQ:TARS) and Xencor (NASDAQ:XNCR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, media sentiment, earnings, institutional ownership, analyst recommendations, risk, valuation and profitability. Do institutionals and insiders believe in TARS or XNCR? 90.0% of Tarsus Pharmaceuticals shares are held by institutional investors. 9.0% of Tarsus Pharmaceuticals shares are held by company insiders. Comparatively, 4.8% of Xencor shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media refer more to TARS or XNCR? In the previous week, Tarsus Pharmaceuticals had 2 more articles in the media than Xencor. MarketBeat recorded 8 mentions for Tarsus Pharmaceuticals and 6 mentions for Xencor. Tarsus Pharmaceuticals' average media sentiment score of 1.11 beat Xencor's score of 0.94 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xencor 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate TARS or XNCR? Tarsus Pharmaceuticals currently has a consensus price target of $66.67, indicating a potential upside of 35.06%. Xencor has a consensus price target of $22.25, indicating a potential upside of 158.72%. Given Xencor's higher possible upside, analysts plainly believe Xencor is more favorable than Tarsus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tarsus Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71Xencor 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has stronger valuation and earnings, TARS or XNCR? Tarsus Pharmaceuticals has higher revenue and earnings than Xencor. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTarsus Pharmaceuticals$182.95M11.39-$115.55M-$2.33-21.18Xencor$146.93M4.17-$232.62M-$2.40-3.58 Is TARS or XNCR more profitable? Tarsus Pharmaceuticals has a net margin of -31.13% compared to Xencor's net margin of -121.52%. Xencor's return on equity of -25.75% beat Tarsus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tarsus Pharmaceuticals-31.13% -32.36% -21.04% Xencor -121.52%-25.75%-18.19% Which has more volatility and risk, TARS or XNCR? Tarsus Pharmaceuticals has a beta of 0.81, meaning that its share price is 19% less volatile than the S&P 500. Comparatively, Xencor has a beta of 0.82, meaning that its share price is 18% less volatile than the S&P 500. SummaryTarsus Pharmaceuticals beats Xencor on 10 of the 16 factors compared between the two stocks. Get Xencor News Delivered to You Automatically Sign up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XNCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XNCR vs. The Competition Export to ExcelMetricXencorMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$606.25M$2.59B$5.86B$10.15BDividend YieldN/A56.51%5.68%4.59%P/E Ratio-3.5823.5374.5225.93Price / Sales4.17697.48539.62123.65Price / CashN/A171.1637.5660.44Price / Book0.895.3712.166.29Net Income-$232.62M$32.95M$3.28B$270.77M7 Day Performance0.58%1.31%0.98%3.36%1 Month Performance10.97%8.31%7.20%6.41%1 Year Performance-58.69%0.29%63.06%28.26% Xencor Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XNCRXencor3.9125 of 5 stars$8.60+1.2%$22.25+158.7%-59.8%$606.25M$146.93M-3.58280TARSTarsus Pharmaceuticals2.7356 of 5 stars$56.89-1.3%$66.67+17.2%+63.1%$2.43B$182.95M-24.4250Positive NewsInsider TradeIDYAIDEAYA Biosciences3.9755 of 5 stars$23.39-13.9%$45.77+95.7%-31.1%$2.38B$7M-6.1780Trending NewsAnalyst ForecastAnalyst RevisionHigh Trading VolumeOCULOcular Therapeutix3.9197 of 5 stars$12.71-6.5%$17.20+35.3%+51.3%$2.37B$63.72M-9.93230MLYSMineralys Therapeutics3.0042 of 5 stars$35.93+3.2%$36.60+1.9%+219.2%$2.31BN/A-10.0928Analyst ForecastIBRXImmunityBio2.4923 of 5 stars$2.41+0.4%$10.75+346.1%-28.5%$2.27B$14.74M-5.02590Analyst ForecastDNLIDenali Therapeutics4.3728 of 5 stars$15.50+0.5%$33.50+116.1%-45.3%$2.26B$330.53M-5.54430Positive NewsIRONDisc Medicine3.2528 of 5 stars$61.91+1.9%$98.30+58.8%+24.3%$2.11BN/A-13.8530Positive NewsHigh Trading VolumeBEAMBeam Therapeutics2.8405 of 5 stars$19.94-4.5%$48.45+143.0%-10.7%$2.11B$63.52M-4.43510CNTACentessa Pharmaceuticals3.1965 of 5 stars$18.03+14.6%$31.45+74.5%+64.9%$2.11B$6.85M-10.07200Insider TradeHigh Trading VolumeBLTEBelite Bio2.7892 of 5 stars$67.51+2.7%$96.67+43.2%+40.8%$2.09BN/A-43.5510News CoveragePositive News Related Companies and Tools Related Companies Tarsus Pharmaceuticals Alternatives IDEAYA Biosciences Alternatives Ocular Therapeutix Alternatives Mineralys Therapeutics Alternatives ImmunityBio Alternatives Denali Therapeutics Alternatives Disc Medicine Alternatives Beam Therapeutics Alternatives Centessa Pharmaceuticals Alternatives Belite Bio Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XNCR) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredCollege grad makes $64,000 a monthIt's easy to feel like you've missed out on the biggest stock market boom of the century. But if you want t...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xencor, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xencor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
